Free Trial

BioLineRx Q2 2024 Earnings Report

BioLineRx logo
$0.10 +0.00 (+3.45%)
As of 04:00 PM Eastern

BioLineRx EPS Results

Actual EPS
$0.01
Consensus EPS
-$0.08
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

BioLineRx Revenue Results

Actual Revenue
$5.39 million
Expected Revenue
$3.93 million
Beat/Miss
Beat by +$1.46 million
YoY Revenue Growth
N/A

BioLineRx Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

BioLineRx Earnings Headlines

BioLineRx says current cash to provide runway through 2H26
Outperform BTC without owning any crypto?
I want to let you in on what may be the hottest crypto discovery of all time… One that has NOTHING to do with creating a crypto wallet or touching ANY risky coin for that matter. Instead, it’s a way that could let regular folks like you and me target 10X the possible results you’d expect from buying Bitcoin … in just a fraction of the time It sounds nuts… trust me I know that… But just as I would hate for you to jump into any risky crypto asset… That’s exactly how I would hate for you to miss out on what could be a safer and better way to benefit from the crypto bull run of 2024. Which is why I’m giving you an opportunity to get all the details of this iconic crypto discovery with you for the first time ever… completely free…
BioLineRx Issues Letter to Shareholders
BioLineRx (NASDAQ:BLRX) Now Covered by StockNews.com
See More BioLineRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioLineRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioLineRx and other key companies, straight to your email.

About BioLineRx

BioLineRx (NASDAQ:BLRX), a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

View BioLineRx Profile

More Earnings Resources from MarketBeat